Search

Amir P Tamiz

from Silver Spring, MD
Age ~51

Amir Tamiz Phones & Addresses

  • 9413 Crosby Rd, Silver Spring, MD 20910 (301) 565-0736 (301) 328-0697
  • San Antonio, TX
  • Washington, DC
  • 10728 Caminito Bravura, San Diego, CA 92108
  • 3030 Science Park Rd, San Diego, CA 92121
  • 3920 Ingraham St, Pacific Beach, CA 92109 (858) 272-0284
  • 3827 Acosta Rd, Fairfax, VA 22031 (703) 425-4275
  • Sanger, CA
  • 9413 Crosby Rd, Silver Spring, MD 20910 (301) 565-0736

Education

Degree: Graduate or professional degree

Publications

Us Patents

Non-Covalent Inhibitors Of Urokinase And Blood Vessel Formation

View page
US Patent:
6586405, Jul 1, 2003
Filed:
Dec 7, 2000
Appl. No.:
09/733645
Inventors:
Joseph Edward Semple - San Diego CA
Michael I. Weinhouse - Escondido CA
Odile Esther Levy - San Diego CA
Edwin L. Madison - San Diego CA
Amir P. Tamiz - San Diego CA
Assignee:
Corvas International, Inc. - San Diego CA
International Classification:
C07K 506
US Classification:
514 19, 514 18, 530331
Abstract:
Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have P1 a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

Monomeric And Dimeric Heterocycles, And Therapeutic Uses Thereof

View page
US Patent:
6605621, Aug 12, 2003
Filed:
Jul 30, 2002
Appl. No.:
10/209170
Inventors:
Alan P. Kozikowski - Princeton NJ
Gian Luca Araldi - San Diego CA
Amir P. Tamiz - Washington DC
Assignee:
Georgetown University - Washington DC
International Classification:
A01N 4340
US Classification:
514320
Abstract:
The invention provides compounds of formula(I): wherein X, L, and X have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinsons disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.

Matriptase Inhibitors And Methods Of Use

View page
US Patent:
7019019, Mar 28, 2006
Filed:
Dec 18, 2003
Appl. No.:
10/740946
Inventors:
David F. Duncan - San Diego CA,
L. Josue Alfaro-Lopez - San Marcos CA,
Mallareddy Komandla - San Diego CA,
Odile Esther Levy - San Diego CA,
Ofir Moreno - Del Mar CA,
Joseph E. Semple - San Diego CA,
Amir P. Tamiz - San Diego CA,
Assignee:
Dendreon Corporation - Seattle WA
International Classification:
A61K 31/44
A61K 31/425
A61K 31/38
C07D 333/22
C07D 211/72
US Classification:
514352, 514369, 514438, 546312, 548205, 549 77
Abstract:
The present invention provides matriptase inhibitors and compositions thereof useful for treating cancer. Martripase is a trypsin-like serine protease active in the development of cancerous conditions, such as tumors and metastasis of cancer.

Aromatic Heterocyclic Non-Covalent Inhibitors Of Urokinase And Blood Vessel Formation

View page
US Patent:
7262211, Aug 28, 2007
Filed:
Dec 4, 2002
Appl. No.:
10/309781
Inventors:
Amir P. Tamiz - San Diego CA,
L. Josue Alfaro-Lopez - San Marcos CA,
Odile Esther Levy - San Diego CA,
Joseph Edward Semple - San Diego CA,
Assignee:
Dendreon Corporation - Seattle WA
International Classification:
A61K 31/4412
C07D 211/04
US Classification:
514346, 546223, 546225, 546245
Abstract:
Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have at a group having a guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.

Inhibition Of Gliadin Peptides

View page
US Patent:
2011027, Nov 10, 2011
Filed:
May 6, 2009
Appl. No.:
12/991658
Inventors:
Sefik Alkan - Baltimore MD,
Amir Tamiz - Silver Spring MD,
Kelly Marie Kitchens - Laurel MD,
Malarvizhi Durai - Ellicott City MD,
Neil Poloso - Rockville MD,
Rosa A. Carrasco - Baltimore MD,
International Classification:
A61K 38/08
C07K 5/09
C07K 5/103
C07K 5/083
C07K 5/097
A61P 3/00
C07K 5/093
A61K 38/06
A61K 38/07
A61P 3/10
A61P 17/00
C07K 7/06
C07K 5/087
US Classification:
514 69, 530328, 530329, 530330, 530331, 514 217, 514 216, 514 218, 514 219, 514 186
Abstract:
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability and peptide translocation across biological barriers are provided. Such diseases include celiac disease, necrotizing enterocolitis, diabetes, cancer, inflammatory bowel diseases, asthma, COPD, excessive or undesirable immune response, gluten sensitivity, gluten allergy, food allergy, rheumatoid arthritis, multiple sclerosis, immune-mediated or type 1 diabetes mellitus, systemic lupus erythematosus, psoriasis, scleroderma and autoimmune thyroid diseases.

Peptide Conjugates

View page
US Patent:
2012002, Feb 2, 2012
Filed:
Jun 24, 2011
Appl. No.:
13/168734
Inventors:
Amir TAMIZ - Silver Spring MD,
Sefik Alkan - Baltimore MD,
International Classification:
A61K 38/08
A61K 38/07
A61P 3/10
A61K 39/385
A61K 39/395
A61K 38/20
A61K 38/18
C07K 17/00
A61P 35/00
US Classification:
424 852, 530330, 530329, 514 219, 514 218, 514 69, 514 193, 5303917, 530322, 530351, 4241781, 514 76, 514 217, 4241931
Abstract:
The present invention provides novel peptide conjugates. Peptide conjugates of the invention can be used as therapeutic agents. Peptide conjugates invention may also be used to deliver one or more additional active agents. The present invention also provides methods for the treatment of disease by administering to a subject suffering from the disease a composition comprising a peptide conjugate of the invention, optionally.

Mimetic Peptides Derived From Collagen Type Iv And Their Use For Treating Angiogenesis- And Lymphagiogenesis-Dependent Diseases

View page
US Patent:
2013031, Nov 28, 2013
Filed:
Dec 12, 2011
Appl. No.:
13/992998
Inventors:
Aleksander S. Popel - Lutherville MD,
Elena V. Rosca - Baltimore MD,
Jacob E. Koskimaki - Baltimore MD,
Corban G. Rivera - Baltimore MD,
Niranjan B. Pandey - White Marsh MD,
Amir P. Tamiz - Silver Spring MD,
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
C07K 14/78
US Classification:
514 133, 530300, 530326, 530328, 530327, 514 172, 435375
Abstract:
Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.

Monomeric And Dimeric Heterocycles, And Therapeutic Uses Thereof

View page
US Patent:
6440996, Aug 27, 2002
Filed:
Oct 7, 1999
Appl. No.:
09/414106
Inventors:
Alan P. Kozikowski - Princeton NJ
Gian Luca Araldi - San Diego CA
Amir P. Tamiz - Washington DC
Assignee:
Georgetown University - Washington DC
International Classification:
A61K 31445
US Classification:
514316, 514326, 514332, 546186, 546187, 546189, 546191, 546209, 546228, 548131, 549425, 549426
Abstract:
The invention provides compounds of formula (I): wherein X and X are substituted piperidine, cyclohexane, or tetrahydropyran rings, and L is a linking group between X and X ; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinsons disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.
Amir P Tamiz from Silver Spring, MD, age ~51 Get Report